

SUMMARY OF PRODUCT CHARACTERISTICS

- 1. NAME OF VETERINARY MEDICINAL PRODUCT**
Piperazine Citrate Worm Tablets
- 2. QUALITATIVE AND QUANTITATIVE COMPOSITION**
Active Ingredient: Piperazine Citrate, 500mg/tablet
- 3. PHARMACEUTICAL FORM**
Tablet.
- 4. PHARMACOLOGICAL PROPERTIES**

Summary Presentation of the Active Ingredient

Piperazine Citrate is an anthelmintic of low toxicity with a high efficiency against ascarids and some other nematodes.

Pharmacodynamic Properties

Piperazine acts to block neuromuscular transmission in the parasite by hyperpolarizing the nerve membrane, which leads to flaccid paralysis. It also blocks succinate production by the worm. The parasites, paralysed and depleted of energy, are expelled by peristalsis. It is active against the ascarids *Toxocara canis*, *Toxocara cati*/ roundworm, *Toxascaris leonine* and hookworms.

Pharmacokinetic Properties

Piperazine is rapidly absorbed from the GI tract, and piperazine base can be detected in the urine as early as 30 minutes after administration. The excretion rate is maximal at 1 – 8hr, and excretion is practically complete within 24hrs.

ATC Vet Code QP52AH01

5. CLINICAL PARTICULARS

5.1 Target species

Cat, Dog.

5.2 Indications for use, specifying the target species

Piperazine Citrate is indicated for the treatment and control of intestinal infections/ infestations of dogs and cats, and may be used from 2 weeks of age.

5.3 Contra-indications

Whilst piperazine salts have few side effects and are of low toxicity, care should be taken, especially with kittens and puppies, to ensure that the correct dosage is calculated by weighing the animal prior to

administration of the drug. Animals weighing less than 1.25kg should be treated with a suitable anthelmintic licensed for this purpose.

Do not repeat treatment if vomiting occurs shortly after dosing.

Do not administer more than 6 tablets in a single dose. If no vomiting occurs the remaining dose may be given after 3 hours.

5.4 Undesirable effects, frequency and seriousness

Transient neurological effects and urticarial reactions have occasionally been noted.

5.5 Special precautions for use

Care should be exercised when giving piperazine to patients with a history of epilepsy and severe renal dysfunction.

5.6 Use during Pregnancy and Lactation

Consult a veterinary surgeon before treating pregnant animals.

5.7 Interaction with other medicaments and other forms of interaction

None known

5.8 Posology (dosage) and method of administration

Puppies and Kittens

200mg/kg as a single dose (1 tablet per 2.5kg bodyweight).

1st dose: 2 weeks of age

2nd dose: 2 weeks later

Subsequent doses: every 2 weeks of age until 3 months of age and then at 3 monthly intervals.

Nursing Bitches and Queens

They should be treated at 2 weeks after giving birth and every 2 weeks until weaning. It is advisable to treat bitches and queens at the same time as the puppies or kittens.

Older dogs and cats

200mg/kg as a single dose (1 tablet per 2.5kg body weight) at 9 months of age. Repeat treatment at 3 monthly intervals.

Do not repeat the treatment if vomiting occurs shortly after dosing.

Do not administer more than 6 tablets in a single dose. If no vomiting occurs the remaining dose may be given after 3 hours.

5.9 Overdose

Acute overdose

Piperazine has a wide safety margin, and acute overdose is unlikely. Where it does occur however, there may be symptoms of neurotoxicity. There is no known specific antidote.

Chronic overdose

Piperazine Citrate tablets are a single dose treatment. Chronic overdose is therefore not an issue.

5.10 Special warnings for each target species

None

5.11 Withdrawal periods

Not applicable.

5.12 Special precautions to be taken by the person administering the product to animals

Wash hands immediately after administering the tablets.

6. PHARMACEUTICAL PARTICULARS

6.1 Incompatibilities

None known

6.2 Shelf life

3 years

6.3 Special precautions for storage

Protect from light. DO NOT STORE ABOVE 25°C. Store in a dry place.

6.4 Nature and contents of container

White cylindrical polypropylene containers (securitainer) with white tamper evident snap top polyethylene closure, containing 500 tablets, 75mm diameter x 130mm high.

6.5 Special precautions for disposal of unused product or waste materials, if any

None.

7. MARKETING AUTHORISATION HOLDER

Ayrton Saunders Ltd
9 Arkwright Road
Astmoor Industrial Estate
Runcorn
Cheshire
WA7 1NU

8. MARKETING AUTHORISATION NUMBER

Vm 16431/3003

9. DATE OF THE FIRST AUTHORISATION

14th October 1994

10. DATE OF REVISION OF THE TEXT

November 2022